Brenner Michael J, Fox Ida K, Kawamura David H, Yu Vivian M, Lowe James B, Hunter Daniel A, Mackinnon Susan E
Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
Laryngoscope. 2004 Mar;114(3):570-6. doi: 10.1097/00005537-200403000-00034.
OBJECTIVES/HYPOTHESIS: The immunosuppressive agent FK506 has been shown in many studies to enhance nerve regeneration and to accelerate functional recovery after immediate nerve repair. However, in clinical practice the diagnosis and treatment of patients with peripheral nerve injuries is often delayed. The study investigated whether FK506 would retain its neuroregenerative properties when nerve repair and initiation of FK506 therapy were delayed for 7 days.
In vivo laboratory study.
Thirty-two Lewis rats underwent tibial nerve transection and were randomly assigned to four experimental groups: immediate repair with FK506 treatment, immediate repair without FK506 treatment, 7-day delayed repair with FK506 treatment, and 7-day delayed repair without FK506 treatment. Treated animals received daily subcutaneous injections of 2 mg/kg FK506. Serial walking track measurements were performed at 14, 16, and 18 days after nerve repair. On day 18 after repair, peripheral nerves were injected with a fluorescent tracer for retrograde labeling. On day 21, peripheral nerves and spinal cords were harvested for histomorphometric analysis and motor neuron cell body counts, respectively.
Animals that underwent immediate repair with FK506 had significantly higher fiber counts and percentages of nerve than the other three groups (P <.05) but did not show statistically significant earlier functional recovery. The remaining three groups had intermediate levels of nerve regeneration that were not significantly different. Retrograde abled motor neurons counts were decreased in animals with delayed nerve repair that received no FK506 (P <.05).
In a rat tibial nerve transection model, the neuroregenerative effects of FK506 diminished markedly when repair and initiation of FK506 therapy were delayed by 7 days.
目的/假设:多项研究表明,免疫抑制剂FK506可促进神经再生,并加速即时神经修复后的功能恢复。然而,在临床实践中,外周神经损伤患者的诊断和治疗往往会延迟。本研究调查了神经修复和FK506治疗开始延迟7天时,FK506是否仍能保持其神经再生特性。
体内实验室研究。
32只Lewis大鼠接受胫神经横断术,并随机分为四个实验组:即时修复并给予FK506治疗、即时修复不给予FK506治疗、延迟7天修复并给予FK506治疗、延迟7天修复不给予FK506治疗。接受治疗的动物每天皮下注射2mg/kg FK506。在神经修复后第14、16和18天进行连续的行走轨迹测量。在修复后第18天,向周围神经注射荧光示踪剂进行逆行标记。在第21天,分别采集周围神经和脊髓进行组织形态计量分析和运动神经元细胞体计数。
即时修复并给予FK506治疗的动物,其纤维计数和神经百分比显著高于其他三组(P<.05),但在功能恢复方面未显示出统计学上的显著提前。其余三组的神经再生水平处于中等,无显著差异。未接受FK506治疗的延迟神经修复动物的逆行标记运动神经元计数减少(P<.05)。
在大鼠胫神经横断模型中,当神经修复和FK506治疗开始延迟7天时,FK506的神经再生作用明显减弱。